Phase II trial of gemcitabine, epirubicin, and G-CSF in patients with metastatic pancreatic cancer

被引：0
|
作者：
Raderer, M
Kornek, GV
Valencak, J
Lenauer, A
Flebiger, W
Greul, R
Lang, F
Schneeweiss, B
Depisch, D
Scheithauer, W
机构：
[1] Univ Vienna, Dept Internal Med 1, A-1010 Vienna, Austria
[2] AoKH Kirchdorf Krems, Dept Internal Med, Krems, Austria
[3] Wr Neustadt, Dept Surg, Vienna, Austria
[4] Neunkirchen Gen Hosp, Dept Surg, Vienna, Austria
来源：
ANNALS OF ONCOLOGY | 1998年 / 9卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
648
引用
收藏
页码：169 / 169
页数：1
相关论文
共 50 条
  • [41] A phase II trial of imatinib mesylate in patients with metastatic pancreatic cancer
    Gharibo, Mecide
    Patrick-Miller, Linda
    Zheng, Ling
    Guensch, Lisa
    Juvidian, Parisa
    Poplin, Elizabeth
    PANCREAS, 2008, 36 (04) : 341 - 345
  • [42] Sequential epirubicin (E) and gemcitabine (G) in combination with paclitaxel (P) in advanced breast cancer:: A phase II trial
    Spagnolo, P
    Rimondini, S
    Degli Esposti, R
    Cavallo, G
    Benedetti, G
    Marrocolo, F
    Idà, N
    Crinò, L
    ANNALS OF ONCOLOGY, 2000, 11 : 48 - 48
  • [43] NCCTG phase II trial of bevacizumab, gemcitabine, oxaliplatin in patients with metastatic pancreatic adenocarcinoma.
    Kim, G. P.
    Oberg, A.
    Kabat, B.
    Sing, A.
    Hedrick, E.
    Campbell, D.
    Alberts, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 206S - 206S
  • [44] Dose-dense epirubicin and paclitaxel with G-CSF: a study of decreasing intervals in metastatic breast cancer
    R I Lalisang
    E E Voest
    J A Wils
    J W Nortier
    F L Erdkamp
    H F Hillen
    J Wals
    H C Schouten
    G H Blijham
    British Journal of Cancer, 2000, 82 : 1914 - 1919
  • [45] Gemcitabine plus celecoxib in patients with advanced or metastatic pancreatic adenocarcinoma - Results of a phase II trial
    Dragovich, Tomislav
    Burris, Howard, III
    Loehrer, Patrick
    Von Hoff, Daniel D.
    Chow, Sherry
    Stratton, Steven
    Green, Sylvan
    Obregon, Yrma
    Alvarez, Irene
    Gordon, Michael
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2008, 31 (02): : 157 - 162
  • [46] Dose-dense epirubicin and paclitaxel with G-CSF: a study of decreasing intervals in metastatic breast cancer
    Lalisang, RI
    Voest, EE
    Wils, JA
    Nortier, JW
    Erdkamp, FL
    Hillen, HF
    Wals, J
    Schouten, HC
    Blijham, GH
    BRITISH JOURNAL OF CANCER, 2000, 82 (12) : 1914 - 1919
  • [47] A phase II trial of epirubicin plus paclitaxel in metastatic breast cancer
    Carmichael, J
    Jones, A
    Hutchinson, T
    SEMINARS IN ONCOLOGY, 1997, 24 (05) : 44 - 47
  • [48] A randomized phase II trial of nab-paclitaxel and gemcitabine with tarextumab or placebo in patients with untreated metastatic pancreatic cancer
    Hu, Zishuo Ian
    Bendell, Johanna C.
    Bullock, Andrea
    LoConte, Noelle K.
    Hatoum, Hassan
    Ritch, Paul
    Hool, Hugo
    Leach, Joseph W.
    Sanchez, James
    Sohal, Davendra P. S.
    Strickler, John
    Patel, Ravindranath
    Wang-Gillam, Andrea
    Firdaus, Irfan
    Yu, Kenneth H.
    Kapoun, Ann M.
    Holmgren, Eric
    Zhou, Lei
    Dupont, Jakob
    Picozzi, Vincent
    Sahai, Vaibhav
    O'Reilly, Eileen M.
    CANCER MEDICINE, 2019, 8 (11): : 5148 - 5157
  • [49] Randomized phase II trial of panitumumab (P), erlotinib (E), and gemcitabine (G) versus erlotinib-gemcitabine in patients with untreated, metastatic pancreatic adenocarcinoma
    Kim, G. P.
    Foster, N. R.
    Salim, M.
    Flynn, P. J.
    Moore, D. F., Jr.
    Zon, R.
    Mowat, R. B.
    McCullough, A.
    Meyers, J. P.
    Alberts, S. R.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (04)
  • [50] Pegylated G-CSF Combined with mFOLFIRINOX for Advanced Pancreatic Cancer Patients
    Chen, Peng
    Lei, Jiexin
    Wu, Yue
    Zhou, Benhong
    INTERNAL MEDICINE, 2020, 59 (06) : 877 - 877
12345